niacinamide has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 4 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harrison, IF | 1 |
| Powell, NM | 1 |
| Dexter, DT | 1 |
| Anderson, DW | 2 |
| Bradbury, KA | 2 |
| Schneider, JS | 2 |
| Jia, H | 1 |
| Li, X | 2 |
| Gao, H | 1 |
| Feng, Z | 1 |
| Zhao, L | 1 |
| Jia, X | 1 |
| Zhang, H | 1 |
| Liu, J | 1 |
4 other studies available for niacinamide and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease.
Topics: Acetylation; Acetylcysteine; Animals; Cell Death; Disease Models, Animal; Dopaminergic Neurons; Hist | 2019 |
Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Humans; | 2008 |
Neuroprotection in Parkinson models varies with toxin administration protocol.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antigens, Nuclear; Axons; Benzothiazoles; Bio | 2006 |
High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Cell Line, Tumor; Cell Survival; Disease Mo | 2008 |